. "[41E691688E1F]" . . "receptor; HER-2"@en . . . "3"^^ . "Radov\u00E1, Lenka" . . . . "4"^^ . "Zp\u016Fsob zji\u0161t\u011Bn\u00ED senzitivity pacient\u016F s n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm na l\u00E9\u010Dbu inhibitory HER-2 receptoru"@cs . "Univerzita Palack\u00E9ho v Olomouci, L\u00E9ka\u0159sk\u00E1 fakulta; Masaryk\u016Fv onkologick\u00FD \u00FAstav, Brno" . "302709" . "Method For Determining The Sensitivity Of Patients Suffering From A Cancer Disease To Inhibitor Therapy of HER-2 receptor"@en . "RIV/61989592:15110/11:10223030!RIV12-MSM-15110___" . "2011-08-03+02:00"^^ . "Zp\u016Fsob zji\u0161t\u011Bn\u00ED senzitivity pacient\u016F s n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm na l\u00E9\u010Dbu inhibitory HER-2 receptoru" . . "Zp\u016Fsob zji\u0161t\u011Bn\u00ED senzitivity pacient\u016F s n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm na l\u00E9\u010Dbu inhibitory HER-2 receptoru"@cs . . "Hajd\u00FAch, Mari\u00E1n" . . "Dziechciarkov\u00E1, Marta" . "\u00DA\u0159ad pr\u016Fmyslov\u00E9ho vlastnictv\u00ED" . . . "P(ED0030/01/01), Z(MSM6198959216)" . . "Zp\u016Fsob zji\u0161t\u011Bn\u00ED senzitivity pacient\u016F s n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm na l\u00E9\u010Dbu inhibitory HER-2 receptoru" . . "The invention relates to a method for determining the sensitivity of patients suffering from a cancer disease towards targeted biological therapy based on the inhibition of signaling pathways of the members of HER family (e.g., HER-1, HER-2, HER-3 and HER-4) by determining the expression of the biomarker S6 kinase or its post-translationally modified form or of the biomarkers of the activation of S6 kinase or their post-translationally modified forms in the tumor."@en . "Svoboda, Marek" . "RIV/61989592:15110/11:10223030" . . . "243691" . . . "Zp\u016Fsob zji\u0161t\u011Bn\u00ED senzitivity pacient\u016F s n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm na l\u00E9\u010Dbu inhibitory HER-2 receptoru stanoven\u00EDm biomarkeru pSer{SUP}235/236{/SUP} posttransla\u010Dn\u011B modifikovan\u00E9 formy ribosom\u00E1ln\u00EDho proteinu S6 v n\u00E1doru. Je-li pSer{SUP}235/236{/SUP} posttransla\u010Dn\u011B modifikovan\u00E1 forma ribosom\u00E1ln\u00EDho proteinu S6 v n\u00E1doru p\u0159\u00EDtomna, je n\u00E1dor rezistentn\u00ED k biologick\u00E9 l\u00E9\u010Db\u011B inihibitory HER-2 receptoru jako je nap\u0159. trastuzumab. Naopak v p\u0159\u00EDpad\u011B, \u017Ee tato forma proteinu S6 nen\u00ED v n\u00E1doru p\u0159\u00EDtomna, je n\u00E1dor na l\u00E9\u010Dbu inhibitory HER-2 receptoru senzitivn\u00ED a pacient m\u00E1 celkov\u011B p\u0159\u00EDznivou progn\u00F3zu." . . . . "15110" . . . . "Prague" . "Method For Determining The Sensitivity Of Patients Suffering From A Cancer Disease To Inhibitor Therapy of HER-2 receptor"@en . "Zp\u016Fsob zji\u0161t\u011Bn\u00ED senzitivity pacient\u016F s n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm na l\u00E9\u010Dbu inhibitory HER-2 receptoru stanoven\u00EDm biomarkeru pSer{SUP}235/236{/SUP} posttransla\u010Dn\u011B modifikovan\u00E9 formy ribosom\u00E1ln\u00EDho proteinu S6 v n\u00E1doru. Je-li pSer{SUP}235/236{/SUP} posttransla\u010Dn\u011B modifikovan\u00E1 forma ribosom\u00E1ln\u00EDho proteinu S6 v n\u00E1doru p\u0159\u00EDtomna, je n\u00E1dor rezistentn\u00ED k biologick\u00E9 l\u00E9\u010Db\u011B inihibitory HER-2 receptoru jako je nap\u0159. trastuzumab. Naopak v p\u0159\u00EDpad\u011B, \u017Ee tato forma proteinu S6 nen\u00ED v n\u00E1doru p\u0159\u00EDtomna, je n\u00E1dor na l\u00E9\u010Dbu inhibitory HER-2 receptoru senzitivn\u00ED a pacient m\u00E1 celkov\u011B p\u0159\u00EDznivou progn\u00F3zu."@cs . .